Intermountain Precision Genomics Discontinuing Laboratory Services

Intermountain Health will close and divest its Precision Genomics Laboratory service on February 1, 2024. 

Myriad Genetics, a Utah-based company and an Intermountain partner and fellow pioneer in genetic testing and precision medicine, will acquire the TheraMap: Solid Tumor and TheraMap: Liquid Biopsy tests. Two other tests currently performed by Precision Genomics, RxMatch and TheraMap Myeloid Malignancies, will be discontinued. Comparable tests will be available to order through non-Intermountain precision medicine laboratories. The roles of eighteen employees will be eliminated as part of the disposition, and severance packages and career-transition assistance will be available to affected employees.

Since its creation in 2014, Intermountain Precision Genomics has advanced the use of genomics to improve patient care and made discoveries to influence the future of medicine. Over the past ten years, the precision medicine market has rapidly evolved, new partners have entered, and this work has become became financially unsustainable. Intermountain providers will continue to use genomic testing from Myriad and other partners to provide excellent and cutting-edge care to those we serve.

Culmination Bio, an Intermountain subsidiary, will continue to provide clinical and diagnostic aspects and care process models for precision medicine. Culmination Bio will also continue carrying out research from the HerediGene project in partnership with the Intermountain Biorepository.

###